What is simca? – Bloomberg
The United States Food and Drug Administration (FDA) approved simca, a synthetic version of a bacterium, for human use in September.
A key ingredient is a molecule known as the C-terminal region, which has been shown to protect against a number of viruses.
The agency has given the company until May 20 to show that it can produce a vaccine that is safe and effective.
Simca has been in development for several years and was approved by the FDA for use in the treatment of the coronavirus, which caused a massive pandemic in 2013 and 2016.
The U.S. Food and Human Rights Commission (FHRC) said last month it is “not aware of any human vaccine currently available to treat simca-associated diseases.”
It’s unclear if the agency’s approval will be enough to allow the company to manufacture a vaccine.
In a statement, a spokeswoman for Simca said the company is “excited to be partnering with FDA on this important development.”
Simca spokesman Andrew Leung said in a statement that the company will “vigorously pursue” the FDA approval.
The FDA approved simcas treatment in January, according to Reuters.
The agency said the drug is likely to be available for use by 2020.
The U.K.-based company is developing a synthetic strain of simca that is resistant to many of the viruses causing the pandemic, such as coronaviruses and coronaviral encephalitis (CXE).
The company is also working on a strain that can be grown in a lab and use in vaccines, Reuters reported.
Simca, which is based in Cambridge, Mass., began commercial sales in 2015.
As with many synthetic drugs, the company uses a natural product, which may include animal cells, and uses a synthetic process to produce the vaccine.
The company does not say whether it is currently using its drug to treat coronavillosis.